Equities researchers at HC Wainwright increased their FY2026 earnings estimates for shares of Oncolytics Biotech in a ...

Oncolytics Biotech faces financial struggles and unclear pelareorep efficacy signals. Learn why ONCY stock's risks outweigh ...

Investment analysts at HC Wainwright cut their FY2028 earnings per share (EPS) estimates for Oncolytics Biotech in a research ...

Oncolytics Biotech (ONCY) has disclosed a new risk, in the Corporate Activity and Growth category. Oncolytics Biotech faces significant business ...

Oncolytics Biotech ( ($ONCY) ) has released its Q4 earnings. Here is a breakdown of the information Oncolytics Biotech presented to its investors.

Maxim lowered the firm’s price target on Oncolytics (ONCY) to $3 from $5 and keeps a Buy rating on the shares. The firm is adjusting its model ...

RBC Capital lowered the firm’s price target on Oncolytics (ONCY) to C$5 from C$6 and keeps an Outperform rating on the shares.Optimize Your ...

CNW/ -- (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for oncology, today ...

Oncolytics Biotech Inc (ONCY) reports significant advancements in cancer research despite increased net loss and leadership uncertainties.

USA News Group News Commentary – As cancer rates continue to climb worldwide, the push for innovative treatments has never ...